AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback